H. Lundbeck AS - Company Profile
Powered by
All the data and insights you need on H. Lundbeck AS in one report.
- Save hours of research time and resources with
our up-to-date H. Lundbeck AS Strategy Report
- Understand H. Lundbeck AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of Alzheimer's disease, migraine, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US and other countries. Lundbeck is headquartered in Valby, Denmark.
H. Lundbeck AS premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pharmaceuticals: | Ebixa |
Disease Areas: | Azilect |
Alzheimer's Disease | Serdolect |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In March, the company received approval for Abilify Maintena 960 mg (aripiprazole) from the European Commission (EC). |
2023 | Contracts/Agreements | In July, Lundbeck Export entered into a partnership with Bora Pharmaceuticals under which Bora will be responsible for sales and marketing of Lundbeck’s products through Bora’s specialized hospital, clinic, and drug store channels in Taiwan. |
2023 | Contracts/Agreements | In May, the company collaborated with Alloy Therapeutics for discovery of novel biologics therapies. |
Competitor Comparison
Key Parameters | H. Lundbeck AS | Novo Nordisk AS | Viatris Inc | Orifarm Group A/S | Leo Pharma AS |
---|---|---|---|---|---|
Headquarters | Denmark | Denmark | United States of America | Denmark | Denmark |
City | Valby | Bagsvaerd | Canonsburg | Odense | Ballerup |
State/Province | - | - | Pennsylvania | - | - |
No. of Employees | 5,681 | 66,015 | 38,000 | 2,316 | 5,252 |
Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Lars Soren Rasmussen | Chairman | Executive Board | 2018 | 65 |
Charl van Zyl | Chief Executive Officer; President | Senior Management | 2023 | 57 |
Joerg Hornstein | Chief Financial Officer; Executive Vice President - Corporate Functions | Senior Management | 2022 | 47 |
Lene Skole-Sorensen | Deputy Chairman | Executive Board | 2015 | 65 |
Keld Flintholm Jorgensen | Executive Vice President - Corporate Business Development & Strategy | Senior Management | 2019 | 53 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer